Company Performance Metrics
AdEVBio is a preclinical-stage biotechnology company that develops adiponectin-based therapeutics using engineered extracellular vesicles. The company focuses on chronic cardiometabolic diseases that are associated with reduced adiponectin levels, such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Its platform engineers
extracellular vesicles to carry high levels of adiponectin, using the body’s own cellular messengers as a delivery system. These investigational biologics are designed to restore metabolic balance, improve insulin sensitivity, and modulate inflammation through hormone replacement targeted at specific tissues. AdEVBio concentrates on translating this adiponectin-EV platform into therapeutic candidates for long-term management of chronic metabolic and cardiovascular conditions.
